US2019117625A1PendingUtilityA1

Method of treating multiple sclerosis

69
Assignee: HOPITAUX PARIS ASSIST PUBLIQUEPriority: Jul 26, 2012Filed: Dec 21, 2018Published: Apr 25, 2019
Est. expiryJul 26, 2032(~6 yrs left)· nominal 20-yr term from priority
Inventors:Frédéric Sedel
A61K 9/0019A61K 31/4188A61P 25/28A61K 9/0053A61K 9/20A61K 45/06A61K 9/48A61P 25/00A61K 31/395
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides a composition for oral administration that is formulated for human administration in unit dosage form and contains as its sole active ingredient at least 100 mg biotin per unit dose.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A composition for oral administration, wherein said composition is formulated for human administration in unit dosage form and contains as its sole active ingredient at least 100 mg biotin per unit dose. 
     
     
         2 . The composition of  claim 1 , comprising as an active ingredient around 100 mg biotin. 
     
     
         3 . The composition of  claim 1 , wherein said unit dose is in the form of a gel capsule, a tablet, a film-coated tablet, a lozenge or a pill. 
     
     
         4 . The composition of  claim 1 , further comprising an excipient. 
     
     
         5 . The composition of  claim 4 , wherein the excipient is talc or microcrystalline cellulose.

Join the waitlist — get patent alerts

Track US2019117625A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.